


Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases.

Janick Selves, Marion Jaffrelot, Anne Pascale Laurenty, Samira Icher, Nadim Farés, Anne Cécile Brunac,
Marie Danjoux, Julie Meilleroux, Christine Toulas, Edith Chipoulet, Rosine Guimbaud



INSTITUT UNIVERSITAIRE
DU CANCER DE TOULOUSE
Oncopole

MMR system = MisMatch Repair



DNA Mismatch Repair system

Mismatches : **microsatellites**

4 proteins,

Functional **heterodimers** :

- MSH2/MSH6
- PMS2/MLH1


dMMR : role in oncogenesis

Indications for somatic MMR testing:

**Lynch
syndrome
screening**

**Prognosis factor for Colorectal
and (gastric, endometrial)
cancer:
(neo) adjuvant chemotherapy ?**

**All M+ cancers :
anti PD1/PDL1
Immunotherapy
Clinical trials ++**




**Increasing of the indications ++
Not only colorectal / endometrial cancers**

Methods used in clinical practice

Molecular Biology (MB)	Immunohistochemistry (IHC)
<ul style="list-style-type: none">• MSI high : instability ≥ 2 microsatellites• MSI low : 1 unstable microsatellite• MSS : 5 stable microsatellites <p>[Pentaplex PCR , NCI panel (1)]</p>	<p>Testing 4 MMR proteins MLH1/PMS2, MSH2/MSH6: Retained staining: pMMR Loss of protein staining : dMMR</p>

Sensitivity / Concordance :

- 
- IHC : **sensitive** (92.3%), very **specific** (100%) (2)
 - **Concordance IHC/ MB** : 95 to 99 % (3, 4)

(1) Xicola RM et al. J Natl Cancer Inst. 2007
(2) Lindor NM et Al. J Clin Oncol. 2002
(3) Cicek MS et Al.. J Mol Diagn. 2011
(4) Bonnet et al. Dig Liver Dis. 2012

The dMMR profiles






Classical pattern

MB

MSI-H

IHC

**Coupled loss
of proteins:**
MLH1/PMS2
MSH2/MSH6



The dMMR profiles

Classical pattern

MB

MSI-H

IHC

**Coupled loss
of proteins:**
MLH1/PMS2
MSH2/MSH6

Atypical patterns

MSS

**Loss of
protein**

MSI-H

**No coupled
loss of protein**
Or retained
4 proteins

**MSI
LOW**

Materials & Methods

- All MMR testing performed between **2007 and 2017**
- **Cancer Molecular Biology Platform** of Midi-Pyrénées

2007

Colo-rectal cancers

- **1511 analyses**
- **1462 : both IHC + MB analyses (97%)**

2012

All cancers


- **3437 analyses**
- **2338 : both IHC +MB analyses (68%)**

2017


N = 4948
Of which
3800 IHC + MB

Materials & Methods


- All MMR testing performed between **2007 and 2017**
- **Cancer Molecular Biology Platform** of Midi-Pyrénées



Results (n = 97 atypical dMMR)




Controls of the analyses (n = 90/97)



After reviewing : **8 cases were reclassified as typical** (5 colons, 3 endometrium)

89 atypical dMMR cases were confirmed = 15%

Results (n = 89 atypical dMMR)



- Colorectal cancer (CRC)
- GI cancers (no CRC)
- Endometrial carcinoma
- Other tumor types

	PMS2 or MSH6 Isolated loss n = 53	Classical coupled loss of two proteins n = 16	Retained expression of 4 proteins n = 5	Aberrant Loss of protein expression n = 15
MSI-H	43 MSI-H		3 MSI-H	13 MSI-H
MSI low	1 MSI low	8 MSI low	2 MSI low	0 MSI low
MSS	9 MSS	8 MSS		2 MSS



43 cases with a known biological mechanism = « atypical already described » (1,2)

46 cases: « true atypical »

(1) Alpert L et Al. Arch Pathol Lab Med. Avr 2018

(2) Daria Carmela Loconte et Al. Human Pathology. 2014

Results (n = 89)

■ Colorectal cancer (CRC) ■ GI cancers (no CRC) ■ Endometrial carcinoma ■ Other tumor types

PMS2 / MSH6 isolated loss n = 53


43 MSI-H

1 MSI low, 9 MSS

→ 38 CCR / endometrium

73 % genetic syndromes

Lynch ++, 1 Pol-E, 1 CMMR-D



Results (n = 89)


■ Colorectal cancer (CRC) ■ GI cancers (no CRC) ■ Endometrial carcinoma ■ Other tumor types

PMS2 / MSH6 isolated loss n = 53

43 MSI-H | 1 MSI low, 9 MSS

→ 38 CCR / endometrium


73 % genetic syndromes
Lynch ++, 1 Pol-E, 1 CMMR-D



Retained 4 proteins n = 5

3 MSI-H (2 Lynch) | 2 MSI low

Exceptional
Missense mutation ++



Results (n = 89)

■ Colorectal cancer (CRC)
 ■ GI cancers (no CRC)
 ■ Endometrial carcinoma
 ■ Other tumor types

PMS2 / MSH6 isolated loss n = 53

43 MSI-H

1 MSI low, 9 MSS

→ 38 CCR / endometrium

73 % genetic syndromes

Lynch ++, 1 Pol-E, 1 CMMR-D


**Classical MMR coupled loss
n = 16**

8 MSI low, 8 MSS

RARE

False negative Pentaplex PCR ?

Mainly no colorectal cancer : 63% of cases





Retained 4 proteins n = 5

3 MSI-H (2 Lynch)

2 MSI low

**Exceptional
Missense mutation**



Results (n = 89)

■ Colorectal cancer (CRC) ■ GI cancers (no CRC) ■ Endometrial carcinoma ■ Other tumor types

PMS2 / MSH6 isolated loss n = 53


43 MSI-H

1 MSI low, 9 MSS

→ 38 CCR / endometrium

73 % genetic syndromes

Lynch ++, 1 Pol-E, 1 CMMR-D




Classical MMR coupled loss n = 16

8 MSI low, 8 MSS

RARE

False negative Pentaplex PCR ?

Mainly no colorectal cancer :63% of cases




Retained 4 proteins n = 5

3 MSI-H (2 Lynch)

2 MSI low

Exceptional

Missense mutations ++




Aberrant loss of protein n = 15

13 MSI-H

2 MSS

→ MSI ++ : complex mechanism of MMR inactivation ?

4 proteins loss : MLH1 methylation MLH1 + secondary inactivation of MSH6 or MSH2 (1)



Take home messages

- **All atypical results (MB and/or IHC) must be controlled** : to repeat or complete the analyses
- **8% of cases (MB + IHC) are atypical dMMR tumors**
Increasing for non colorectal cancers

Strong diagnosis value for Lynch syndrome or genetic syndromes
- **Biological and therapeutic value ?**
Need to better characterize atypical dMMR cases :
 - Extensive sequencing on going
 - Therapeutic impact for immunotherapy ?

Thank you for your attention !

